Girard B, Ouafik L, Delfino C, Fraboulet S, Oliver C, Boudouresque F
Laboratoire de Cancérologie Expérimentale, EA 2671, IFR Jean Roche, Faculté de médecine Nord, Marseille, France.
Mol Cell Endocrinol. 1999 Aug 20;154(1-2):89-100. doi: 10.1016/s0303-7207(99)00084-2.
Peptidylglycine alpha-amidating monooxygenase (PAM; EC 1.14.17.3) is a bifunctional protein containing two enzymes that act sequentially to catalyse the alpha-amidation of neuroendocrine peptides. Previous studies have demonstrated that alpha-adrenergic stimulation results in an increase in intracellular volume and protein content of cultured neonatal rat myocardial cells. The present study examined the regulated expression of PAM during alpha-adrenergic stimulation. Alpha1-adrenergic stimulation activates the expression and release of PAM from myocytes. Following phenylephrine treatment, myocardial cells displayed a several fold increase in PAM activity, and a 2-4-fold increase in the steady state levels of PAM mRNA. This effect of alpha-adrenergic stimulation was dependent on the concentration and duration of exposure to the agonist, and displayed alpha1-adrenergic receptor specificity. The transcription rate experiments indicated that these alpha-adrenergic effects were not due to increased PAM gene activity, suggesting that a post-transcriptional mechanism was involved. The most common mechanism of post-transcriptional regulation affects cytoplasmic mRNA stability. Cardiomyocytes cultures from atria and ventricles in the presence of 5,6 dichloro-1-beta ribofuranosyl benzamidazole (DRB) showed that phenylephrine treatment increased the half-life of PAM mRNA from 13 +/- 1 to 21 +/- 1 h in atrial cells and from 8 +/- 1 to 12 +/- 1 h in ventricle cells. Analysis of nuclear RNA with probes specific for PAM intron sequences shows that increased PAM expression after phenylephrine treatment was not due to intranuclear stabilisation of the primary transcript. Protein kinase C inhibitors H7 and GF109203x, completely blocked the phenylephrine stimulated PAM expression. These results suggest that alpha-adrenergic agonist induces PAM mRNA levels by increasing its stability in the cytoplasm. They indicate that PAM gene expression augments through a H7 and GF109203x sensitive pathway, involving the activation of protein kinase C.
肽基甘氨酸α-酰胺化单加氧酶(PAM;EC 1.14.17.3)是一种双功能蛋白,包含两种酶,它们依次作用以催化神经内分泌肽的α-酰胺化。先前的研究表明,α-肾上腺素能刺激会导致培养的新生大鼠心肌细胞的细胞内体积和蛋白质含量增加。本研究检测了α-肾上腺素能刺激过程中PAM的表达调控。α1-肾上腺素能刺激激活了PAM从心肌细胞的表达和释放。用去氧肾上腺素处理后,心肌细胞的PAM活性增加了几倍,PAM mRNA的稳态水平增加了2至4倍。α-肾上腺素能刺激的这种作用取决于激动剂的浓度和暴露持续时间,并表现出α1-肾上腺素能受体特异性。转录速率实验表明,这些α-肾上腺素能效应并非由于PAM基因活性增加,提示涉及转录后机制。转录后调控最常见的机制影响细胞质mRNA的稳定性。在存在5,6-二氯-1-β-D-呋喃核糖基苯甲酰胺(DRB)的情况下,来自心房和心室的心肌细胞培养物显示,去氧肾上腺素处理使心房细胞中PAM mRNA的半衰期从13±1小时增加到21±1小时,在心室细胞中从8±1小时增加到12±1小时。用针对PAM内含子序列的探针分析核RNA表明,去氧肾上腺素处理后PAM表达增加并非由于初级转录本在核内的稳定。蛋白激酶C抑制剂H7和GF109203x完全阻断了去氧肾上腺素刺激的PAM表达。这些结果表明,α-肾上腺素能激动剂通过增加其在细胞质中的稳定性来诱导PAM mRNA水平。它们表明PAM基因表达通过H7和GF109203x敏感途径增强,涉及蛋白激酶C的激活。